Alzheimer's and other diseases could be linked to contagious bacteriophages

New research from the Human Microbiology Institute has shown that many diseases, from Alzheimer’s to cancer and others, could be linked to bacterial viruses, a finding that could indicate those diseases are in fact contagious.

The chronic inflammation associated with such diseases as inflammatory bowel disease, Crohn’s disease, cancer, Alzheimer’s, autism, diabetes, heart conditions, rheumatoid arthritis and more, according to a release from the HMI, could be enabled by microbiota diseases.

The bacterial viruses, or bacteriophages, that cause microbiota diseases were not previously considered mammalian or human pathogens, the researchers said, but their study, published in Gut Pathogens, shows they may in fact be an indirect trigger because of their association with “leaky gut” syndrome.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

Leaky gut arises due to the permeability of the intestinal lumen, which the scientists found in rats treated with bacteriophages. This increased permeability can allow inflammation-causing bacteria to travel more readily in the body, and the researchers have reason to believe neurodegenerative diseases and others can result.

"This is a revolutionary discovery that completely changes views on the causes of incurable diseases like Alzheimer's, Parkinson's, dementia and others," lead researcher George Tetz of HMI said. "To our knowledge, this is the first study to indicate that bacteriophages can cause human diseases. Infection from bacteriophages that are known solely to target bacteria may be harmful to mammals and humans, opening new ways to prevent and cure these diseases."

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.